fermer

Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?

Pelegrin, M.; Naranjo-Gomez, M.; Piechaczyk, M.

Trends Microbiol

2015-10 / vol 23 / pages 653-665

Abstract

Monoclonal antibodies (mAbs) are increasingly being considered as agents to fight severe viral diseases. So far, they have essentially been selected and used on the basis of their virus-neutralizing activity and/or cell-killing activity to blunt viral propagation via direct mechanisms. There is, however, accumulating evidence that they can also induce long-lasting protective antiviral immunity by recruiting the endogenous immune system of infected individuals during the period of immunotherapy. Exploiting this property may revolutionize antiviral mAb-based immunotherapies, with benefits for both patients and healthcare systems.

Lire sur PubMed

S0966-842X(15)00154-7 [pii] 10.1016/j.tim.2015.07.005

1878-4380 (Electronic) 0966-842X (Linking)

IGMM team(s) involved in this publication

Toutes les publications